Anti-βGal-hCD3InvivoGen Kontakt z doradcą
Anti-βGal-hCD3 is a bispecific antibody that binds to two sites: E. coli β-galactosidase (β-Gal)and hCD3, part of the T cell receptor. It is used as a negative control for Anti-hCD19-CD3 bispecific antibody that, alike Blinatumomab, engages unstimulated T cells to proliferate and exert cytotoxic activity on CD19-positive lymphoma cells [1,2].
- Krishnamurthy A. & Jimeno A., 2017. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. S0163-7258(17)30293-0.
- Bargou R. et al., 2008. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell– Engaging Antibody. Science. 321(5891):974-7.